Status:
COMPLETED
Study of Atorvastatin Dose Dependent Reduction of Proteinuria
Lead Sponsor:
Laval University
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.
Eligibility Criteria
Inclusion
- Age of 18 and over
- Stage 3 or 4 chronic kidney disease (modified MDRD)
- proteinuria of \> 1g/d on ACEi and/or ARB, or proteinuria of \> 1g/d with intolerance or contraindication to ACEi and/or ARB
- blood pressure \< 130/80 mmHg or \< 140/90 mmHg in patients with five or more antihypertensive drugs
- stable renal function
Exclusion
- rapid progression of renal failure
- immunosuppressive therapy within the past 3 months
- need a renal replacement therapy within 8 months
- definite history of chronic liver disease, or abnormal liver function
- evidence of active inflammatory muscle disease
- definite previous adverse reaction to a statin
- concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin)
- child bearing potential
- known to be poorly compliant with clinic visits or prescribed medication
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00768638
Start Date
October 1 2008
End Date
June 1 2014
Last Update
April 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôtel-Dieu de Québec Hospital
Québec, Quebec, Canada, G1R2J6